On 3/1/24, Eagle Pharmaceuticals Inc (NASDAQ: EGRX) stock enjoyed a major increase of 10.6%, closing at $6.48. However, this advance was accompanied by below average trading volume at 68% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 10.4% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, EGRX is expected to continue to be a modest Value Builder.
Eagle Pharmaceuticals has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Eagle Pharmaceuticals has a very high Appreciation Score of 97 but a very low Power Rating of 7, triggering the Neutral Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment